4887-94-9

Usage

Uses

Used in Pharmaceutical Industry:
1H-Benzimidazole,2-chloro-5-methyl-(9CI) is used as a key intermediate in the design and synthesis of prostate cancer antigen-1 (PCA-1/ALKBH3) inhibitors. These inhibitors serve as anti-prostate cancer drugs, targeting the PCA-1 enzyme that plays a role in cancer cell survival and proliferation. 1H-Benzimidazole,2-chloro-5-methyl-(9CI)'s unique structure allows for the development of potent and selective inhibitors, offering a promising therapeutic approach for prostate cancer treatment.
Used in Chemical Synthesis:
1H-Benzimidazole,2-chloro-5-methyl-(9CI) is also utilized in the synthesis of unsymmetrical 2,2’-bisbenzimidazole sulfide, a compound of pharmacological interest. The synthesis of 1H-Benzimidazole,2-chloro-5-methyl-(9CI) involves the use of 1H-Benzimidazole,2-chloro-5-methyl-(9CI) as a starting material, which can be further modified and functionalized to create novel molecules with potential applications in the pharmaceutical industry. The versatility of 1H-Benzimidazole,2-chloro-5-methyl-(9CI) in chemical synthesis makes it a valuable building block for the development of new drugs and therapeutic agents.

Upstream product

• 5400-75-9 5-methyl-1,3-dihydro-2H-benzimidazol-2-one 
• 496-72-0 4-methyl-1,2-diaminobenzene 

Downstream Products

• 1453097-57-8 C₁₈H₁₆N₄O 
• 1453097-59-0 C₂₃H₁₈N₄O 
• 1453097-13-6 1-(5-methyl-1H-benzimidazol-2-yl)-3-methyl-4-(phenylmethyl)-1H-pyrazol-5-ol 
• 93102-21-7 2-hydrazinyl-5-methyl-1H-benzo[d]imidazole 
• 1453097-22-7 C₂₀H₁₇F₃N₄O 
• 1453097-38-5 C₂₀H₂₀N₄O₂ 
• 1453097-21-6 4-[(3,4-dichlorophenyl)methyl]-3-methyl-1-(5-methyl-1H-benzimidazol-2-yl)-1H-pyrazol-5-ol 
• 1453097-37-4 C₁₉H₁₇ClN₄O 
• 1453097-19-2 4-[(4-chlorophenyl)methyl]-3-methyl-1-(5-methyl-1H-benzimidazol-2-yl)-1H-pyrazol-5-ol 
• 1453097-36-3 C₁₉H₁₇FN₄O 
• 1453097-24-9 4-[[4-(1,1-dimethylethyl)phenyl]methyl]-3-methyl-1-(5-methyl-1H-benzimidazol-2-yl)-1H-pyrazol-5-ol 
• 1453097-20-5 3-methyl-1-(5-methyl-1H-benzimidazol-2-yl)-4-[(4-phenylphenyl)methyl]-1H-pyrazol-5-ol 

Relevant academic research and scientific papers

NOVEL BENZIMIDAZOLE DERIVATIVE AND USE THEREFOR

To provide a compound that has excellent oral absorbency and can inhibit Prostate Cancer Antigen-1(PCA-1) enzyme activity.SOLUTION: The present invention provides a compound represented by formula (I) or a pharmaceutically acceptable salt thereof. (Ris H,

Preparation method of 2-substituted benzimidazole derivative

The invention discloses a preparation method of a 2-substituted benzimidazole derivative 1-(5-methyl-1H-benzo[d]imidazole-2-yl) piperidine-4-carboxylic acid. 5-methyl-2-nitroaniline is taken as an initial raw material and subjected to reduction, ring closure, chlorination and a nucleophilic reaction, and a target product is obtained. The compound is an important medical intermediate.

Discovery of a Selective Aurora A Kinase Inhibitor by Virtual Screening

Here we report the discovery of a selective inhibitor of Aurora A, a key regulator of cell division and potential anticancer target. We used the atom category extended ligand overlap score (xLOS), a 3D ligand-based virtual screening method recently developed in our group, to select 437 shape and pharmacophore analogs of reference kinase inhibitors. Biochemical screening uncovered two inhibitor series with scaffolds unprecedented among kinase inhibitors. One of them was successfully optimized by structure-based design to a potent Aurora A inhibitor (IC50 = 2 nM) with very high kinome selectivity for Aurora kinases. This inhibitor locks Aurora A in an inactive conformation and disrupts binding to its activator protein TPX2, which impairs Aurora A localization at the mitotic spindle and induces cell division defects. This phenotype can be rescued by inhibitor-resistant Aurora A mutants. The inhibitor furthermore does not induce Aurora B specific effects in cells.

NOVEL BENZIMIDAZOLE DERIVATIVE AND USE THEREOF

The present invention aims to provide a compound capable of inhibiting PCA-1 that can be a target for a novel treatment method of various diseases, and pharmaceutical use of the compound. A compound represented by the formula (I): wherein each symbol is a

Design and synthesis of prostate cancer antigen-1 (PCA-1/ALKBH3) inhibitors as anti-prostate cancer drugs

A series of 1-aryl-3,4-substituted-1H-pyrazol-5-ol derivatives was synthesized and evaluated as prostate cancer antigen-1 (PCA-1/ALKBH3) inhibitors to obtain a novel anti-prostate cancer drug. After modifying 1-(1H-benzimidazol-2-yl)-3,4-dimethyl-1H-pyrazol-5-ol (1), a hit compound found during random screening using a recombinant PCA-1/ALKBH3, 1-(1H-5- methylbenzimidazol-2-yl)-4-benzyl-3-methyl-1H-pyrazol-5-ol (35, HUHS015), was obtained as a potent PCA-1/ALKBH3 inhibitor both in vitro and in vivo. The bioavailability (BA) of 35 was 7.2% in rats after oral administration. As expected, continuously administering 35 significantly suppressed the growth of DU145 cells, which are human hormone-independent prostate cancer cells, in a mouse xenograft model without untoward effects.

POLYCYCLIC ORGANIC COMPOUNDS, RETARDATION LAYER AND COMPENSATION PANEL ON THEIR BASE

This invention relates to polycyclic organic compounds of general structural formula (I): wherein Y is a predominantly planar polycyclic system being at least partially aromatic, W1, W2, and W3 are different groups providing solubility in an organic solvent, and sum (n1 +n2+n3) is 1, 2, 3, 4, 5, 6, 7 or 8. The polycyclic organic compounds are substantially transparent for electromagnetic radiation in the visible spectral range and are capable of forming supramolecules in the organic solvent.

Design, syntheses, and structure-activity relationships of novel NPY Y5 receptor antagonists: 2-{3-Oxospiro[isobenzofuran-1(3H),4′-piperidin]-1′-yl}benzimidazole derivatives

Design, syntheses, and structure-activity relationships of a novel class of 2-{3-oxospiro[isobenzofuran-1(3H),4′-piperidin]-1′-yl}benzimidazole NPY Y5 receptor antagonists are described. The benzimidazole structures were newly designed based on the urea linkage of our prototype Y5 receptor antagonists (2 and 3). By optimizing substituents on the benzimidazole core part of the lead compound 5a, we were able to develop a potent, orally available, and brain-penetrable Y5 selective antagonist (5k). Crown Copyright

Design of potent, orally available antagonists of the transient receptor potential vanilloid 1. Structure-activity relationships of 2-piperazin-1-yl-1H- benzimidazoles

The vanilloid receptor-1 (VR1 or TRPV1) is a membrane-bound, nonselective cation channel that is predominantly expressed by peripheral neurons sensing painful stimuli. TRPV1 antagonists produce antihyperalgesic effects in animal models of inflammatory and neuropathic pain. Herein, we describe the synthesis and the structure-activity relationships of a series of 2-(4-pyridin-2- ylpiperazin-1-yl)-1H-benzo-[d]imidazoles as novel TRPV1 antagonists. Compound 46ad was among the most potent analogues in this series. This compound was orally bioavailable in rats and was efficacious in blocking capsaicin-induced flinch in rats in a dose-dependent manner. Compound 46ad also reversed thermal hyperalgesia in a model of inflammatory pain, which was induced by complete Freund's adjuvant (CFA).

BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS VANILLOID RECEPTOR LIGANDS

Compounds of formula (I) are useful in the treatment of vanilloid-receptor-meditated diseases, such as inflammatory or neuropathic pain and diseases involving sensory nerve function such as asthma, rheumatoid arthritis, osteoarthritis, inflammatory bowel disorders, urinary incontinence, migraine and psoriasis.